KR20230049580A - 트리아졸론 화합물 - Google Patents

트리아졸론 화합물 Download PDF

Info

Publication number
KR20230049580A
KR20230049580A KR1020227037225A KR20227037225A KR20230049580A KR 20230049580 A KR20230049580 A KR 20230049580A KR 1020227037225 A KR1020227037225 A KR 1020227037225A KR 20227037225 A KR20227037225 A KR 20227037225A KR 20230049580 A KR20230049580 A KR 20230049580A
Authority
KR
South Korea
Prior art keywords
amino
pyrimidin
methyl
triazolo
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227037225A
Other languages
English (en)
Korean (ko)
Inventor
길스 알버트 브라운
마일스 스튜어트 콘그리브
스테펜 필립 앤드류
조나단 스테펜 메이슨
프란체스카 데플로리언
니겔 앨런 스웨인
Original Assignee
헵테얼즈 테라퓨틱스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 헵테얼즈 테라퓨틱스 리미티드 filed Critical 헵테얼즈 테라퓨틱스 리미티드
Publication of KR20230049580A publication Critical patent/KR20230049580A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020227037225A 2020-03-26 2021-03-25 트리아졸론 화합물 Pending KR20230049580A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062994954P 2020-03-26 2020-03-26
US62/994,954 2020-03-26
PCT/EP2021/057808 WO2021191380A1 (en) 2020-03-26 2021-03-25 Triazolone compounds

Publications (1)

Publication Number Publication Date
KR20230049580A true KR20230049580A (ko) 2023-04-13

Family

ID=75302568

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227037225A Pending KR20230049580A (ko) 2020-03-26 2021-03-25 트리아졸론 화합물

Country Status (8)

Country Link
US (1) US12552799B2 (https=)
EP (1) EP4126871B1 (https=)
JP (1) JP7709454B2 (https=)
KR (1) KR20230049580A (https=)
CN (1) CN115867550B (https=)
AU (1) AU2021241886A1 (https=)
CA (1) CA3177057A1 (https=)
WO (1) WO2021191380A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025512384A (ja) 2022-04-13 2025-04-17 ギリアード サイエンシーズ， インコーポレイテッド Ｔｒｏｐ－２発現がんを治療するための併用療法
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
ATE457988T1 (de) 2006-06-26 2010-03-15 Schering Corp A2a-adenosin-rezeptor-antagonisten
JP2011513417A (ja) * 2008-03-04 2011-04-28 シェーリング コーポレイション アデノシンＡ２ａ受容体アンタゴニストとして使用するための１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オンおよびピラゾロ［４，３−ｅ］−１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オン化合物
AU2011306358B2 (en) 2010-09-24 2014-08-14 Impetis Biosciences Ltd. Fused tricyclic compounds as adenosine receptor antagonist
EP3277689B1 (en) 2015-04-03 2019-09-04 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
AU2018233367B2 (en) 2017-03-16 2021-08-12 Jiangsu Hengrui Medicine Co., Ltd. Heteroaryl[4,3-c]pyrimidine-5-amine derivative, preparation method therefor, and medical uses thereof
PL3611174T3 (pl) * 2017-04-07 2022-08-08 Medshine Discovery Inc. Pochodne [1,2,4]triazolo[1,5-c]pirymidyny jako inhibitor receptora a2a
EP3774813A4 (en) * 2018-04-08 2021-11-17 BeiGene, Ltd. PYRAZOLOTRIAZOLOPYRIMIDE DERIVATIVES AS A2A RECEPTOR ANTAGONIST
WO2020010197A1 (en) * 2018-07-05 2020-01-09 Incyte Corporation Fused pyrazine derivatives as a2a / a2b inhibitors

Also Published As

Publication number Publication date
JP2023519363A (ja) 2023-05-10
JP7709454B2 (ja) 2025-07-16
EP4126871B1 (en) 2024-05-08
US20230146796A1 (en) 2023-05-11
WO2021191380A1 (en) 2021-09-30
US12552799B2 (en) 2026-02-17
AU2021241886A1 (en) 2022-10-27
EP4126871A1 (en) 2023-02-08
CN115867550B (zh) 2025-01-03
CN115867550A (zh) 2023-03-28
CA3177057A1 (en) 2021-09-30

Similar Documents

Publication Publication Date Title
AU2019243289B2 (en) Heterobicyclic inhibitors of MAT2A and methods of use for treating cancer
CN112513029B (zh) 含氮芳基磷氧化物类衍生物、其制备方法和应用
JP6159028B2 (ja) Ｓｙｋ阻害剤
CN117957226A (zh) 作为sos1抑制剂的杂环化合物及其用途
EP2435438A1 (en) Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
JP7675094B2 (ja) トリアゾロン化合物
JP7709454B2 (ja) トリアゾロン化合物
CN115867280B (zh) 用于抗癌的5-氨基-8-(4-吡啶基)-[1,2,4]三唑并[4,3-c]嘧啶-3-酮化合物
CN115433211A (zh) 吡嗪并吡啶酮类蛋氨酸腺苷转移酶2a抑制剂
US20250114345A1 (en) Compounds and compositions as cbp/p300 degraders and uses thereof
HK40088927B (en) Triazolone compounds
HK40088927A (en) Triazolone compounds
TW202610638A (zh) 包含維爾納症候群解旋酶抑制劑之組成物及其使用方法
HK40049450B (en) Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
HK40049450A (en) Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
EA041815B1 (ru) Гетеробициклические ингибиторы mat2a и способы использования для лечения злокачественной опухоли
EA046747B1 (ru) Имидазопиримидины и триазолопиримидины в качестве ингибиторов a2а/a2b

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902